• Elicio Therapeutics

  Led · Grant · Sep 2022

  Elicio Therapeutics is an immuno-oncology vaccine developer working on precision vaccines, immune stimulants and cell therapies. The company announced it signed a subscription agreement with GKCC, LLC. That agreement is for a private placement described as a strategic investment. The private placement’s total proceeds are expected to be approximately $7 million before deduction of fees. The announcement was reported on December 25, 2023 by DoNews. No operating metrics or prior financings are detailed in the article. Elicio Therapeutics is a clinical-stage biotechnology company engineering Amphiphile (AMP) lymph node-targeted immunotherapies and vaccines. Its proprietary AMP platform delivers antigens and immunomodulators to lymph nodes by hitchhiking on albumin to amplify T cell responses. The company is developing a pipeline that includes ELI-002, a KRAS-targeting therapeutic vaccine currently dosing in Cohort 3 of a Phase 1/2 AMPLIFY-201 trial. GIRF awarded Elicio a $2.8 million grant to advance preclinical and translational research on two additional candidates, ELI-007 (BRAF V600E peptide vaccine) and ELI-008 (p53 hotspot mutation peptide vaccine). ELI-007 and ELI-008 are being pursued as multivalent cancer vaccines to target shared neoantigens across tumor types such as colorectal cancer, melanoma and NSCLC. The AMP platform originated at MIT and is being applied across cancers and infectious disease indications to promote durable tumor-specific immunity. Elicio Therapeutics develops immunotherapies that precisely target lymph nodes via its Amphiphile (AMP) platform to amplify anti-tumor and infectious-disease immune responses. Its lead program, ELI-002, is an AMP KRAS vaccine combining AMP-CpG adjuvant and AMP mKRAS peptides aimed at a broad spectrum of KRAS mutations. Proceeds from the financing will advance ELI-002 into clinical trials, with initial patient studies planned for the first quarter of 2021. The company describes a pipeline of IND-ready and preclinically validated AMP candidates across therapeutic vaccines, adjuvants, and cell-therapy activators. Elicio works with collaborators including MIT, the National Cancer Institute, Moffitt Cancer Center, Boston Children’s Hospital, and QIMR Berghofer to advance its platform and expand commercial partnerships. The company positions its multi-targeted vaccine approach as differentiated from single-isoform small-molecule KRAS inhibitors. Elicio Therapeutics develops lymph node–targeted Amphiphile immunotherapies, including lead candidate ELI-002, an Amphiphile mKRAS vaccine designed to target seven KRAS mutations that drive the vast majority of mKRAS cancers. The company’s Amphiphile platform is intended to deliver immunogens and cell-therapy activators directly to the lymphatic system to amplify anti-tumor immune responses. ELI-002 has completed preclinical validation, IND‑enabling GLP toxicology studies, GMP manufacturing, and a pre‑IND meeting with the FDA. Elicio plans initial patient studies in pancreatic and colorectal cancer in the first half of 2020, with initial pancreatic patient data expected in the second half of 2020. The company is advancing a broader preclinical pipeline of lymph node–targeted immunotherapies.

No current team members are available.